Epitope specificity of serum antibodies directed against the extracellular domain of myelin oligodendrocyte glycoprotein: Influence of relapses and immunomodulatory treatments.
Only few reports are available on the epitope specificity of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in multiple sclerosis (MS). In the present study we provide a precise characterization of the epitope specificity of serum antibodies directed against the extracellular domain of MOG, including IgG, IgM and IgA immunoglobulin isotypes in 28 relapsing remitting MS patients and report that linear epitopes amino-acid (aa) 37-48 and aa42-53 are immunodominant. Recently experienced relapses intensified the anti-MOG peptide antibody response. Immunomodulatory treatment with interferon-beta or glatiramer-acetate had no major impact on the anti-MOG peptide immunoreactivity after 1 year of therapy.
Khalil
Michael
M
Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.
Reindl
Markus
M
Lutterotti
Andreas
A
Kuenz
Bettina
B
Ehling
Rainer
R
Gneiss
Claudia
C
Lackner
Peter
P
Deisenhammer
Florian
F
Berger
Thomas
T
D000328:Adult; D000595:Amino Acid Sequence; D000906:Antibodies / Q000097:blood*; D000918:Antibody Specificity / Q000502:physiology*; D016022:Case-Control Studies; D000939:Epitopes / Q000097:blood*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000517:prevention & control / Q000628:therapy*; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D063308:Myelin-Oligodendrocyte Glycoprotein; D012372:ROC Curve; D055502:Secondary Prevention; D012680:Sensitivity and Specificity; D013997:Time Factors
D000906:Antibodies; D000939:Epitopes; D007155:Immunologic Factors; C571326:MOG protein, human; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein